Guest Blog–National Cancer Institute Launches the CCDI Molecular Targets Platform

The Molecular Targets Platform is an NCI-supported instance of the  Open Targets Platform with a focus on preclinical pediatric oncology data. It is a tool that supports the identification and prioritization of molecular targets expressed in childhood cancers.   The Molecular Targets Platform builds upon the data and functionality of the Open Targets Platform while also including: The FDA Pediatric Molecular Target Lists (FDA PMTL) Analyses of pediatric oncology datasets from the Open Pediatric Cancer (OpenPedCan) project at the Children’s Hospital of Philadelphia: Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Open Pediatric Brain Tumor Atlas (OpenPBTA) Gabriella Miller Kids […]

Read more

CAC2 Childhood Cancer Community News Digest (July 25- August 7)

Assorted News from the Last Two Weeks: The CCDI Molecular Targets Platform is the National Cancer Institute’s instance of the Open Targets Platform, specific to childhood cancers which will allow researchers to find data from multiple sources on molecular targets—molecules involved in the growth and spread of cancer cells. Identifying these targets, how they affect cancers, and how they interact with drugs can help improve how childhood cancers are treated. To explore the Molecular Targets Platform, visit: moleculartargets.ccdi.cancer.gov. From the Washington Post:  Pushed by parent activists and buoyed by new funding, scientists explore novel strategies to treat deadly pediatric cancers. […]

Read more

Community News: Update on Federal Childhood Cancer Appropriations Process

Update from our colleagues at the Alliance for Childhood Cancer (July 28, 2022): The Senate Appropriations Committee included language to fund the Childhood Cancer STAR Act and the Childhood Cancer Data Initiative fully again this year in its Fiscal Year 2023 Labor-HHS Appropriations bill.  In addition, the FY23 Defense Appropriations bill included many topics related to childhood and AYA cancer research and maintained level funding at $130 million for the Peer Reviewed Cancer Research Program. This step is important to our requests being included in the final appropriations package when Congress considers the next budget. Here are some key sections [...] Read more

CAC2 Childhood Cancer Community News Digest (July 18-24)

Assorted News from Last Week: The Biden administration has selected Monica Bertagnolli, a renowned surgical oncologist, as the next director of the National Cancer Institute. (gated) The Pediatric Oncology Group of Ontario issued its latest report on childhood cancer efforts in Ontario. Bringing next-generation CAR T-cell therapies to children with solid cancers The Food and Drug Administration (FDA) recently approved the combination of the targeted drugs dabrafenib (Tafinlar)and trametinib (Mekinist) for the treatment of people with nearly any type of advanced solid tumor that has a specific mutation in a gene called BRAF. Results were reported from a phase I safety […]

Read more

CAC2 Webinar–Why Foundations Should Collaborate to Fund Research and How the Foundation Match Platform Can Help

As Foundation Match makes its debut, this webinar gave an opportunity to learn more about the platform. In addition, a moderated discussion explored a few of the different motives and approaches that CAC2 member organizations that co-fund research adopted and learned from an investigator about how funding collaboration has the potential to improve the research landscape. Panelists shared why they are excited to join the Foundation Match platform. Panel members include: Donna Ludwinski (Solving Kids’ Cancer) Lisa Ward (Tough2gether Against DIPG/DMG) Julie Guillot (Leukemia & Lymphoma Society Volunteer) Elias Sayour, MD, PhD (Associate Professor of Neurosurgery and Pediatrics, Principal Investigator, [...] Read more

CAC2 Childhood Cancer Community News Digest (July 11-17)

Assorted News from Last Week: Researchers have identified the child cancer patients at greatest risk of developing life-threatening infections, in a crucial step towards the development of an early diagnostic test. A report out this month (highlights) highlights some of the data capacity needs to handle patient-centered outcomes  and also describes how U.S. Department of Health and Human Services (HHS)’s Office of the Assistant Secretary for Planning and Evaluation (ASPE) could help to address these data capacity needs. Intratumoral infusion of an oncolytic virus offered safe and feasible results, along with encouraging efficacy, in pediatric patients with diffuse intrinsic pontine […]

Read more

CAC2 Childhood Cancer Community News Digest (July 4-10)

Assorted News from Last Week: Three things to know if your child is diagnosed with cancer. CNN Correspondent Rene Marsh tells the story of her pediatric cancer journey with her 9-month old son:  “It was worse than a nightmare because I couldn’t wake up from this.” Gilead Sciences has unveiled a new global pediatric drug development center in Ireland that will have 33 job openings by the end of 2022.   Upcoming Webinars, Online Opportunities, and Meetings: Join advocates from around the country for the 2022 Rally for Medical Research! The Hill Day will take place on Wednesday, September 14, with […]

Read more

CAC2 Childhood Cancer Community News Digest (June 27-July 3)

Assorted News from Last Week: Childhood cancer survivors of certain racial and ethnic groups were prone to more hospitalizations for various conditions years down the road. Survivorship Matters Blog:  Recapturing the Dream NCI’s new Molecular Characterization Initiative (MCI) is expanding comprehensive molecular characterization of tumors to children, adolescents, and young adults (AYAs) with newly diagnosed soft tissue sarcomas receiving care at hospitals affiliated with the Children’s Oncology Group. Intratumoral infusion of an oncolytic virus offered safe and feasible results, along with encouraging efficacy, in pediatric patients with diffuse intrinsic pontine glioma (DIPG). Some children with a type of brain cancer called […]

Read more

Guest Blog–National Cancer Institute Expands Molecular Characterization Initiative for Childhood Cancer Research

The National Cancer Institute’s new Molecular Characterization Initiative (MCI) fosters data sharing in childhood cancer research. The program is expanding comprehensive molecular characterization of tumors to children, adolescents, and young adults (AYAs) with newly diagnosed soft tissue sarcomas receiving care at hospitals affiliated with the Children’s Oncology Group. The DNA and RNA in participants’ tumors are analyzed through this voluntary, free program.  This effort is in addition to the previous cohort that targeted the molecular characterization of newly diagnosed central nervous system tumors in children and AYA patients.   Participants’ tumor and blood samples are analyzed in an accredited lab, with […]

Read more

Survivorship Matters Blog: Recapturing the Dream

Survivorship Matters Blog By CAC2 Member Mary Beth Collins, PREP4Gold During his teens, my neuroblastoma survivor Joshua was struggling in every way a person could struggle. Puberty had brought on new long term side effects, and reinvigorated old ones that we thought were behind us. His chemo-induced hearing loss progressed from moderate-to-severe to profound, and his hearing aides became a trigger for his migraines. The combinations of cognitive impact, cluster migraines, and chemo-induced ADHD made education almost impossible. He was doing the best he could on home/hospital care with a teacher who visited the house a few times a week. […]

Read more

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.